BHCM
KROS icon

Brevan Howard Capital Management’s Keros Therapeutics KROS Stock Holding History

Brevan Howard Capital Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$162K Buy
+14,651
New +$226K ﹤0.01% 1945
2025
Q4 		– Sell
-44,874
Closed -$710K – 2067
2025
Q3 		$710K Sell
44,874
-25,275
-36% -$373K ﹤0.01% 1090
2025
Q2 		$936K Buy
70,149
+4,305
+7% +$58.1K 0.01% 1100
2025
Q1 		$671K Buy
65,844
+54,658
+489% +$635K 0.01% 636
2024
Q4 		$177K Buy
11,186
+5,468
+96% +$284K ﹤0.01% 928
2024
Q3 		$332K Buy
+5,718
New +$282K ﹤0.01% 811

Other funds holding KROS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Brevan Howard Capital Management's KROS Position: Q1 2026 in Review

Brevan Howard Capital Management opened a new position in Keros Therapeutics (KROS) in Q1 2026: 14,651 shares worth $162K. The stake represents ﹤0.01% of the portfolio and ranks #1945 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in KROS as recently as Q3 2025.

Brevan Howard Capital Management first reported a position in KROS in Q3 2024 and has held it in 6 quarters since. The position peaked at $936K in Q2 2025. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • Brevan Howard Capital Management held 14,651 shares of Keros Therapeutics worth $162K as of Q1 2026.
  • Keros Therapeutics was a new Brevan Howard Capital Management position in Q1 2026.
  • Keros Therapeutics made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1945 holding.
  • Brevan Howard Capital Management first reported a position in Keros Therapeutics in Q3 2024 and has held it in 6 quarters since.
  • Brevan Howard Capital Management's Keros Therapeutics position peaked at $936K in Q2 2025.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.